share_log

HC Wainwright & Co. Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $50

HC Wainwright & Co. Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $50

HC Wainwright & Co.維持對 Tarsus Pharmicals 的買入,將目標股價提高至 50
Benzinga ·  2023/07/26 06:10

HC Wainwright & Co. analyst Oren Livnat maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and raises the price target from $44 to $50.

HC Wainwright & Co. 分析師奧倫·利夫納特維持Tarsus Pharmicals(納斯達克股票代碼:TARS)的買入,並將目標股價從44美元上調至50美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論